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Summary
Background: An eHealth computer-based tool named ORION was constructed to assist patients in the clinic to appreci-
ate the factors responsible for risks of drug overdose. The aim of this study was to investigate the associations between 
risk perception of overdose, engagement in the ORION tool and willingness to alter overdose risk factors. Methods: 194 
opioid dependent patients participated from 4 countries (UK, N=39; Germany, N=99; Italy, N=40 and Denmark, N=16). 
A structural equation model was fitted (AMOS version 17) to summarise the predicted associations between perceived 
risk and willingness to change risks of opioid overdose. The degree of engagement with the tool (time spent and number 
of changes to overdose risk factors) was explored. Results: A variety of models were fitted and the most parsimonious 
model provided a non-significant difference between the raw data and the specified model: Chi Sq = 16.87, df10, p = .077 
chi sq/df = 1.688. The fit indices: CFI = .991, RMSEA = .066. Pre and post self-assessments of risk towards known fac-
tors linked with overdose were highly correlated. A significant path was found between engagement in the tool and the 
willingness to change one or more risk factors (stand. coeff. = 0.16, p = .04). In addition, the final assessment of the risk 
factors was associated with engagement (stand. coeff. = 0.18, p = .02). Conclusion: The encouragement of drug users to 
engage in exploring changes to their overdose risk when presented on a computer screen appears to increase willingness 
to change risky behaviour.
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1. Introduction
Drug overdose in Europe remains a significant 
cause of avoidable death in young adults. According 
to the most recent estimates from the European Mon-
itoring Centre for Drugs and Drug Addiction [18], 
more than 80 million adults in EU (approx. 25%) are 
reported to have a lifetime use of illicit drugs, with 
cannabis use most frequently reported. An estimated 
1.3 million Europeans were treated for use of illicit 
drugs in 2012 and relevant mortality rate is estimat-
ed to be 17.1 cases per million population in the EU 
[18]. The current scene in Europe is one where drugs 
such as stimulants, synthetics, medicinal products 
and cannabis are becoming an increasingly preva-
lent problem, causing considerable concern, whereas 
drugs such as heroin appear to be stable if not declin-
ing in use. 
DSM 5 Opioid Use Disorder [1], combining 
DSM-IV-TR [2] Opioid Dependence and Abuse, in-
corporates a wide range of illicit and prescribed drugs 
of the opioid class. Opioid use disorders are related to 
severe outcomes, including risk of overdose and pre-
mature mortality [6,30] with standardized mortality 
ratios up to 9.1 (CI: 8.5–9.8) [4]. In particular over-
dose-related mortality accounts for 0.65 (0.55–0.75) 
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deaths per 100 person-years, though pooled overall 
crude mortality rates for people who inject drugs 
range from 5.25 (Asia), to 2.64 (North America) and 
2.31 (Western Europe) [16]. Unfortunately, people 
with opioid use disorders are often poorly aware of 
likely overdose risks [33] reporting distorted beliefs 
about factors associated with overdose [14] with 
limited knowledge and only on few factors such as 
polydrug/polysubstance use [48]. Furthermore, peo-
ple with opioid dependence are often unaware of how 
to effectively prevent and respond to an overdose 
event, and are often unfamiliar even with the use of 
naloxone [21]. More importantly, overdoses seem in 
many cases the result of more or less deliberate risk-
taking, in some cases with no knowledge about po-
tential consequences [39]. Impaired decision making 
is actually a common issue for substance users, who 
show little regard for consequences, and often deny or 
are unaware that they have a problem [8].
1.1. Complex nature of non-fatal drug overdoses
Non-fatal overdoses have been found to predis-
pose to a number of significant chronic morbidities. 
For example, non-fatal overdose has been associated 
with complications to the pulmonary [45], cardiac 
[30] and renal systems. Neurological damage and cog-
nitive impairment [15] are also commonly associated 
with non-fatal illicit drug overdose. Some evidence 
has indicated that non-fatal illicit drug overdose may 
also predict successive risk of overdose mortality [46] 
suggesting that knowledge and previous experience 
of overdose serve only to increase the risk of drug-
related deaths. Risk factors for illicit-drug overdose 
are complex and many. Increased risk of overdose has 
been associated with specific demographic factors 
(male gender, increased age, homelessness) [47,9], 
individual characteristics (individual tolerance, ex-
perience of stress, poor mental health) [6,12,27], en-
vironmental factors (imprisonment history, drug use 
context – alone or with more than 1 person present) 
[12] and importantly, those variables associated with 
the specific drug and drug-related behaviours (drug 
type, drug dose, route of administration, frequency 
of injection, mixing of drugs, use of other substances 
and CNS depressants) [7,22]. 
1.2. Prevention and treatment
In Europe, prevention of illicit drug overdose 
incidences and drug-related mortality has become a 
significant challenge for public health. Interventions 
targeted at reducing harm from drug use are contro-
versial in many EU countries, and overdose preven-
tion measures such as, drug consumption rooms, peer 
take-home naloxone distribution, and overdose re-
sponse training programmes are lacking [19]. Barri-
ers to adequate responses, related to the setting, have 
to do with the legal context, police policies regarding 
overdoses, the scene of the overdose as well as social 
norms among user groups [22,43]. 
E-Health tools provide a way to support be-
havioural changes and nowadays 90% of individuals 
worldwide have access to the internet through mobile 
phone services, including vulnerable populations, 
such as people with substance use disorders (SUD) 
[38]. E-Health technology supporting behavioural 
treatments for SUD, encompasses a wide range of de-
livery formats (e.g., computer-based, smart-phones), 
types of intervention (e.g., brief interventions, behav-
ioural therapy, treatment adherence tools), and has 
been used across various substances (e.g., opioid, co-
caine, alcohol, cannabis, etc.) [31] for a wide range 
of populations (i.e., adults, adolescents and young 
adults, criminal justice populations, postpartum 
women), as well as in many, different settings (addic-
tion specialty treatment programmes, schools, emer-
gency rooms, criminal justice settings) [37]. 
The advantages of e-Health, appropriate for peo-
ple who use opioids, include ease of access and of use 
across settings, delivery of information in an attrac-
tive way, personalization of intervention, enhanced 
confidentiality, reduction of stigmatization [40]. Fur-
thermore, since the vast majority of people with a 
drug problem do not access treatment [44], e-Health 
tools have shown promising results, increasing rates 
of subjects in receipt of care [49]. 
Considering health and social burden related 
to overdoses across Europe, and based on a project 
purposely funded by the European Commission, a 
consortium of researchers from different countries 
developed and tested a computer-based tool named 
ORION to assist patients appreciating the factors re-
sponsible for risks of drug overdose [5]. The purpose 
of the Overdose Risk InfOrmatioN Project (ORION) 
study was to develop an overdose risk information 
tool. The design was to construct this as a computer-
based tool which estimates individual overdose risks 
using a psycho-educational approach. ORION is also 
able to assist clinical staff and to educate opioid de-
pendent individuals to become more aware of the lev-
el of their risk factors associated with potential fatal 
and non-fatal overdose. The ORION tool was based 
upon the premise that the patient’s beliefs about the 
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increased likelihood of a harmful outcome can act as 
powerful motivators for behaviour change [10]. In 
the field of injecting drug-users assessments of risk 
have been devised to help predict health damaging 
behaviour [35]. The raising of risk perceptions has 
been shown in addictive behaviour to have a positive 
effect on reducing this behaviour [13]. A further de-
velopment that has driven patient decision tools is the 
representation of numerical information [23,25]. The 
ORION tool was prompted to include state-of-the-art 
graphics to help represent risk. Hence, a system to 
inform patients about risks associated with a variety 
of important factors linked to overdose behaviour was 
carefully constructed [23]. 
The aim of this study was to investigate the as-
sociations between risk perception of overdose, en-
gagement in the ORION tool and willingness to alter 
overdose risk factors, in a clinical setting across vari-
ous EU member states.
2. Methods
2.1. Setting
Recruitment occurred in treatment centres for 
opioid dependent patients across four European coun-
tries: UK, Germany, Italy and Denmark, in both in- 
and out-patient healthcare settings (NHS Fife Addic-
tion Services, UK, LVR-Hospital in Essen, Germany; 
Monza Regional Addiction Service, Italy; and Aarhus 
University Hospital, Risskov, Denmark).
2.2. Participants
Inclusion criteria were patients attending clini-
cal services for opioid dependence, and aged between 
18 to 55 years. Recruitment included consecutive 
male and female patients. Exclusion criteria were cur-
rent psychotic symptoms, severe learning disabilities, 
acute intoxication and patients who were unable to 
give informed consent for other reasons. 194 opioid 
dependent patients participated in the study (UK, 
N=39; Germany, N=99; Italy, N=40 and Denmark, 
N=16). 155 patients were receiving outpatient (pre-
dominantly opioid maintenance) and 39 patients were 
receiving inpatient treatment for their substance mis-
use. The average age of participants (9 missing cases) 
was 38.8 (SD = 7.9) years. 86% of participants were 
male and 14% female (17 missing cases).
2.3. Materials
The visual design and computer programming 
of The Overdose Risk Information (ORION) tool 
software was undertaken by experts from Keele Uni-
versity, and was designed to reside on a PC laptop 
for flexible utilisation in various clinical settings. The 
main content contained questions about nine known 
risk factors for overdose. These risk factors were 
identified from a systematic review of the literature 
purposively run searching main electronic database 
up to March 2011, as well as discussions with clini-
cal experts from all participating sites and countries. 
The experts had to validate the risk factors identified 
for inclusion, either on the basis of being within the 
control of the individual (e.g. injecting behaviour), 
or particularly relevant to the specific clinical set-
tings (e.g. experience of mental health difficulties). 
Table 1 shows these questions, each having a possi-
ble ‘Yes’ or ‘No’ response. This gives 512 possible 
combinations of ‘Yes’ / ‘No’ responses across the 9 
questions. Applying these combinations to gender 
Table 1. Parameters in the ORION model (note 4, 6 are protective factors)
Revised List - Please answer the following questions with regard to the past 30 days: All questions are yes/no
1 Do you inject drugs?
2 Are there days when you take more than one drug (including alcohol)?
3 Have you recently been released from prison or residential rehab?
4 Are you receiving some form of treatment for taking drugs (including alcohol)?
5 Have you used drugs (including alcohol) when you were alone?
6 Have you tried to reduce your use of drugs (including alcohol)?
7 Have you had an unusually stressful life event (e.g. bereavement, relationship break-up, health problem)?
8 Are you suffering from a psychological condition (e.g. depression)?
9 Have you ever been so intoxicated that you were scared of dying?
Background variables (not in questionnaire)
10 Age-group and gender: 15-24, 25-34, 35-44, 45-54/ M, F
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and age bands yields 4,096 combinations. The ex-
pert ratings from each risk factor were consequently 
combined using linear equations to estimate weight-
ings of risk for entry into the internal software of the 
tool. The initial prototype was approved by experts 
at St Andrews University and then tested in external 
validation to ensure the delivered product was func-
tioning and user friendly. Furthermore University of 
St. Andrews staff ensured quality control to the actual 
coding, programming and platform compatibility of 
the interface and focused on the experience of clinical 
addiction experts and behavioural scientists involved 
in the understanding of risk perception and how risk 
can be presented in a meaningful manner. The crea-
tion of the tool was developed by specialists involved 
in the ORION partnership [17]. 
2.4. Design
This study utilised a within-subjects design, 
whereby participants used the ORION software and 
answered the evaluation questions [5].
2.5. Measures
Three assessments were included in the meas-
urement system: 
1. The primary outcome variable for this study 
was the evaluation question: “is your drug 
and/or alcohol taking behaviour likely to 
change as a result of using this informa-
tion?” This was answered using a 3 category 
rating: ‘Not at all’, ‘Perhaps a little’ and 
‘Yes, a lot’. This was designed to assess in-
tention to change risk factor behaviour as a 
result of access to the ORION tool.
2. The Overdose Risk Awareness Question-
naire consisted of 7 items and asked patients 
to rate the likelihood that a person will suf-
fer a drug overdose on a zero to 10 scale of 
‘no more likely’ to ‘much more likely’. This 
was completed by patients without close su-
pervision on two occasions: pre- and post-
clinic appointment (Cronbach alpha coef-
ficients for pre- and post-completions were 
0.84 and 0.87 respectively).
3. The behavioural response to the tool itself 
was recorded from the software memory 
for each individual respondent. The time (in 
seconds) and the number of changes record-
ed on the 9 risk factors answering scheme to 
change the risk estimate of overdose conse-
quence. The correlation between the number 
of changes made and the time spent making 
changes was 0.61 (p<.01).
2.6. Procedure
Participants were invited by a health profession-
al to use the ORION programme [5]. The tool was 
adopted by four clinical teams in respective teams in 
Denmark, Germany, Italy and Scotland. The services 
selected were partners in the original ORION project 
who had an abiding interest in the development of 
new approaches to addiction services. Hence, there 
was support and interest by all four clinical teams to 
receive training and administer the tool to recruited 
patients. The health professional within the special-
ist team in each centre was available throughout the 
session to help with any issues arising from using the 
programme. They were instructed that they could use 
the programme to explore overdose risk factors. At 
the end of their session they were given a printout 
containing a summary of their risk factor profile.
ORION tool [5] consists of the following steps:
1. Welcome screen – describing the programme 
and legal disclaimer regarding overdose risk 
estimation.
2. Demographic information – prompting the 
users to enter participant number, as well as 
gender and age band.
3. Initial risk assessment questions – nine risk 
assessment questions with drop down menus 
allowing the users to indicate whether or not 
this particular risk factor applies to them.
4. First overdose risk feedback – displayed by 
a black marker placed along a horizontal 
bar ranging from low to high overdose risk, 
which was placed against the overdose risk 
of a non drug user for comparison.
5. Option to Change answers and review of 
modified risk – participants were given the 
option to review their answers and visually 
inspect how different answers are reflected 
in changes in the overdose risk feedback 
graphic (Figure 1). Evaluation questions –
three questions about the cognitive, behav-
ioural and affective impact the software is 
likely to have on the user. Each had three 
answer categories: not at all, a little, very 
much.
6. Debriefing screen – thanking the partici-
pants and explaining that the risk feedback 
- 9 -
G. Humphris et al.: Engagement in an E-health tool (ORION) predicts opioid-dependent patient likelihood of behavioural change 
Figure 1. ORION Dashboard
can be recorded and reviewed at a later time. 
The ORION tool itself recorded the participants' 
responses to the overdose risk questions (screen 3), 
whether or not participants reviewed their answers to 
see how this affects risk (screen 4), and which an-
swers in particular were changed (screen 5) [5].
2.7. Statistical methods
The data were analysed with IBM SPSS Statis-
tic v21 and AMOS Software. Latent variables were 
constructed for risk perception and engagement in the 
ORION Tool. Structural Equation Models (SEMs)
[32] were constructed using the ‘diagrammer’ avail-
able in AMOS [3]. The risk perception questionnaire 
was separated into odd and even numbered questions, 
summed and divided by the number of items to create 
a common sub-scale ranging from 0-10. The advan-
tages of ‘parcelling’ for this type of rating scale data 
for entry into SEM analyses has been well recognised 
[34]. These produced the pre-appointment A1 and 
A2 versions of the risk perception ratings for entry 
into the SEMs. Similarly, post-appointment versions 
B1 and B2 were computed for entry. Various models 
were tested and compared for level of fit to the raw 
data. Conventional fit indices were adopted to assess 
elegance of the model to explain the data, including 
chi-square, Comparative Fit Index (CFI) and Root 
Mean Square Approximation of Error (RMSEA). A 
non-significant chi-square, a CFI >0.95, and RMSEA 
< 0.10 was regarded as suitable criteria for reasonable 
model fit [28]. The relative models were examined to 
provide close fit where possible without over fitting. 
The sample size collected was considered satisfac-
tory for application of these models. Power analysis 
showed that to detect the difference between a close 
fitting model and just satisfactory model (RMSEA of 
zero versus 0.1) was possible at 88% power, alpha at 
5% (df = 10) and a sample size of 190, although ex-
cessive testing was not considered suitable [36]. 
2.8. Research governance
Formal ethics and management approvals were 
secured in all four European clinical centres for the 
ORION protocol and its use.
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3. Results
3.1. Descriptive analysis of risk factors
On average, participants had 4.5 (SD=2.2) risk 
factors. The most prevalent risk factors were using 
drugs alone (68%) and mixing drugs (58%). About 
half of the participants had experienced stressful 
events or had a psychological condition.
3.1.1. Pre-Post intervention Risk Perception scores
The maximum score for the Risk Perception 
measure is 70 where a high score denotes greater risk. 
Both pre- and post- total scores on average were high-
er than the mid range point of 35 (see Table 2). A test 
to determine whether the intervention was success-
ful to raise awareness showed a strong positive effect, 
Within-subjects effects: Time F (1, 147) = 9.86; p = 
0.002; although this effect was sensitive to whether 
the participant was male or female, Time by Gender 
F (1, 147) = 7.62; p = 0.006. 
3.1.2. Descriptive analysis of changes to risk factors 
using ORION tool
Ninety-one participants made at least one 
change (49.2%), while 94 (50.8%) did not. The most 
frequently altered factor was release from prison/re-
hab (28%), injecting drugs (25%) and mixing drugs 
(23%). Among those who made changes, the aver-
age number of changes made was 4.3 (SD=3.3, range 
1-22). The average time spent making changes was 
64.7 seconds (SD=58.5, range 6-320). 
3.1.3. Descriptive analysis of ORION tool evaluation 
questions
Forty-five percent indicated that they would 
consider changing their behaviour. 
3.2. Model fitting
A variety of models were fitted and the most 
parsimonious model provided a non-significant dif-
ference (See Table 3) between the raw data and the 
specified model: Chi Sq = 16.87, df10, p = .077 chi 
sq/df = 1.688. The fit indices were CFI = .991, RM-
SEA = .066 (Table 3). 
The final model (Model 2) presented in Figure 
2 provides the measurement details and specification. 
The improvement in the chi square reduction with a 
single degree of freedom was borderline significance 
(p = 0.06). A single correlated error co-variance was 
added to the model to control for auto-correlation. 
Pre and post self-assessments of risk towards known 
factors linked with overdose were highly correlated 
(0.95). A significant path was found between engage-
ment in the tool and the willingness to change one or 
more risk factors (stand. coeff. = 0.16, p = .04). In 
addition, the final assessment of the risk factors was 
associated with engagement (stand. coeff. = 0.18, p 
= .02). 
Table 2: Risk perception Total Scores before and after ORION tool use
Pre-ORION interven-
tion Post-ORION
Mean 95%CIs Mean 95%CIs
Males 49.6 46.9; 52.2 51.8 48.9; 54.6
Females 37.0 26.14; 47.6 45.6 34.2; 57.1
Within-subjects effects: Time F (1, 147) = 9.86; p = 0.002; Time by Gender F (1, 147) = 7.62; p = 0.006
Table 3: Model comparison between different model specifications
Model description to predict willingness to change risk 
factors Chi sq. df p* CFI RMSEA
1 Direct effect of Risk perception, controlling for engage-ment with ORION Tool 20.32 11 0.04 0.99 0.07
2¥ As 1 + direct effect of engagement with ORION Tool (see Figure 2) 16.88 10 0.08 0.99 0.07
* Note p level greater than 0.05 denotes no significant deviation of raw data from model specification (i.e. reasonable fit) ¥ chi 
square = 3.44, p = 0.06; df = degrees of freedom; CFI= Comparative Fit Index; RMSEA = Root Mean Square Approximation of 
Error
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raise stress levels and this status, interestingly, was 
implicated in patients who discontinued their metha-
done programme and increased their health risks [29]. 
More generally this study suggests that following the 
monitoring of risk perception, this assessment may be 
more effective to encourage behavioural change if in-
dividual characteristics are taken into account such as 
the mediating construct often referred to as ‘readiness 
to change’ [24]. 
A further important finding from this exploration 
of the ORION tool is the importance of engagement 
in the new device within the clinical setting. It will 
be important for the further improvement of the tool 
to develop comprehensive training to assist potential 
users (both professional staff and service users) to 
highlight the risk assessment with example scenarios 
and give advisory instructions to assist uptake of the 
vitally important messages that reside within the en-
gagement of the ORION tool. The significant associa-
tion between the level of engagement, as estimated by 
the number of changes and time spent on the activity 
4. Discussion
The importance of attending to patient risk per-
ception and intervening to prevent drug deaths and 
adverse events has been highlighted in this study. The 
ORION tool successfully increased risk perception 
of participants, especially in women. This finding is 
consistent with the available literature as it has been 
demonstrated that men in general rate their risk to al-
cohol, tobacco and drugs as less than women [26]. 
An interaction was shown between gender and the 
before and after measures of risk perception. Women 
reported an extensive heightening of risk compared to 
men when exposed to the ORION intervention. There 
may be a number of reasons for the risk perceptions 
not rising extensively in certain groups of participants 
such as men. It is known that raising risk perception 
may not be very successful in patients who score 
highly on health worry [20]. It may be that men were 
experiencing greater concerns about their health. This 
chronic status may be responsible for the tendency to 
Figure 2. Structural equation model 2 showing standardised coefficients (n=159) and a single error auto-correlation
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5. Future work
There are two issues that require development. 
They include a theoretical elaboration of possible un-
derlying effects of the tool and also more pragmatic 
technological changes that are now required. The first 
issue is to explore the possibility that patients will 
be investing heavily in compensatory health beliefs. 
That is the patient is often aware of many of the risks 
they expose themselves to but actively process to 
minimise these unsettling risk beliefs by promoting 
the benefits of the methadone service. Patients bar-
gain with themselves to achieve what they consider 
to be an appropriate balance of risk. The advantage 
of the ORION tool may be, with repeated use with a 
patient, that this balance is re-calibrated to achieve an 
acceptable risk level [42]. The second issue to pro-
mote is the translation of this tool to other platforms 
than a laptop device. The software is currently avail-
able free for download, however with greater penetra-
tion of the use of ‘smart’ mobile phone technology, 
the transfer to a wider source of operating systems to 
enable services and users greater access will assist in 
the utilisation of this tool and its modifications. Fore-
most in this development would be in the broadening 
of coverage to include primary care services to also 
increase screening and educational efforts as opportu-
nities will arise to strengthen the messages provided 
in the specialist clinics [11]. 
The ORION eHealth tool is available free to 
download at ‘http://orioneuproject.
com/download-software/’.
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